162 related articles for article (PubMed ID: 24023782)
1. Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients.
Giampieri R; Scartozzi M; Loretelli C; Piva F; Mandolesi A; Lezoche G; Del Prete M; Bittoni A; Faloppi L; Bianconi M; Cecchini L; Guerrieri M; Bearzi I; Cascinu S
PLoS One; 2013; 8(9):e72843. PubMed ID: 24023782
[TBL] [Abstract][Full Text] [Related]
2. Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
Stotz M; Herzog SA; Pichler M; Smolle M; Riedl J; Rossmann C; Bezan A; Stöger H; Renner W; Berghold A; Gerger A
Anticancer Res; 2017 Apr; 37(4):2011-2018. PubMed ID: 28373475
[TBL] [Abstract][Full Text] [Related]
3. Common cancer stem cell gene variants predict colon cancer recurrence.
Gerger A; Zhang W; Yang D; Bohanes P; Ning Y; Winder T; LaBonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; El-Khoueiry A; Kahn M; Lenz HJ
Clin Cancer Res; 2011 Nov; 17(21):6934-43. PubMed ID: 21918173
[TBL] [Abstract][Full Text] [Related]
4. Lumican and versican are associated with good outcome in stage II and III colon cancer.
de Wit M; Belt EJ; Delis-van Diemen PM; Carvalho B; Coupé VM; Stockmann HB; Bril H; Beliën JA; Fijneman RJ; Meijer GA
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S348-59. PubMed ID: 22711178
[TBL] [Abstract][Full Text] [Related]
5. Spatial tumour gene signature discriminates neoplastic from non-neoplastic compartments in colon cancer: unravelling predictive biomarkers for relapse.
Sallinger K; Gruber M; Müller CT; Bonstingl L; Pritz E; Pankratz K; Gerger A; Smolle MA; Aigelsreiter A; Surova O; Svedlund J; Nilsson M; Kroneis T; El-Heliebi A
J Transl Med; 2023 Aug; 21(1):528. PubMed ID: 37543577
[TBL] [Abstract][Full Text] [Related]
6. mTOR Signaling Combined with Cancer Stem Cell Markers as a Survival Predictor in Stage II Colorectal Cancer.
Chang JY; Kim JH; Kang J; Park Y; Park SJ; Cheon JH; Kim WH; Kim H; Park JJ; Kim TI
Yonsei Med J; 2020 Jul; 61(7):572-578. PubMed ID: 32608200
[TBL] [Abstract][Full Text] [Related]
7. IL-32θ inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer.
Bak Y; Kwon T; Bak IS; Hong J; Yu DY; Yoon DY
Oncotarget; 2016 Feb; 7(6):7307-17. PubMed ID: 26824417
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle proteins predict recurrence in stage II and III colon cancer.
Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
[TBL] [Abstract][Full Text] [Related]
9. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
[TBL] [Abstract][Full Text] [Related]
10. Lymph node CXCL17 messenger RNA: A new prognostic biomarker for colon cancer.
Rashad Y; Olsson L; Israelsson A; Öberg Å; Lindmark G; Hammarström ML; Hammarström S; Sitohy B
Tumour Biol; 2018 Sep; 40(9):1010428318799251. PubMed ID: 30198422
[TBL] [Abstract][Full Text] [Related]
11. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of LGR5, Prox1, and Notch1 Biomarkers in Stage II to III Colon Cancer.
Abdelrahman AE; El-Azony A; Elsebai E; Ibrahim HM
Appl Immunohistochem Mol Morphol; 2022 Feb; 30(2):126-135. PubMed ID: 34657081
[TBL] [Abstract][Full Text] [Related]
13. Histopathological Predictors of Recurrence in Stage III Colon Cancer: Reappraisal of Tumor Deposits and Tumor Budding Using AJCC8 Criteria.
Landau MA; Zhu B; Akwuole FN; Pai RK
Int J Surg Pathol; 2019 Apr; 27(2):147-158. PubMed ID: 29992847
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
[TBL] [Abstract][Full Text] [Related]
15. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
[TBL] [Abstract][Full Text] [Related]
16. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
17. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
19. Cancer Stem Cell based molecular predictors of tumor recurrence in Oral squamous cell carcinoma.
Mohanta S; Sekhar Khora S; Suresh A
Arch Oral Biol; 2019 Mar; 99():92-106. PubMed ID: 30641296
[TBL] [Abstract][Full Text] [Related]
20. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis.
Li D; Yan D; Tang H; Zhou C; Fan J; Li S; Wang X; Xia J; Huang F; Qiu G; Peng Z
Ann Surg Oncol; 2009 Dec; 16(12):3499-506. PubMed ID: 19672661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
